(Q35108932)

6 August 2017

1 reference

title

Medical management of endometriosis-associated pain (English)

1 reference

6 August 2017

0 references

1 reference

2

Aydin Arici

1 reference

6 August 2017

Neal G. Mahutte

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699262

24 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12699262

24 December 2023

publication date

1 March 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S0889854502000578?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0889-8545(02)00057-8

https://api.elsevier.com/content/article/PII:S0889854502000578?httpAccept=text/plain

24 December 2023

1 reference

https://api.crossref.org/works/10.1016/S0889-8545(02)00057-8

Obstetrics and Gynecology Clinics of North America

24 December 2023

published in

1 reference

6 August 2017

volume

30

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

133-150

1 reference

Validation study of nonsurgical diagnosis of endometriosis.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Revised American Society for Reproductive Medicine classification of endometriosis: 1996

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

A Comparative Treatment Trial of Endometriosis Using the Gonadotrophin-releasing Hormone Agonist, Nafarelin, and the Synthetic Steroid, Danazol

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Zoladex Endometriosis Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

A randomized, comparative trial of triptorelin depot (D-Trp6-LHRH) and danazol in the treatment of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

The efficacy of drugs in the management of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Stage and localization of pelvic endometriosis and pain

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Endometriosis and pelvic pain: relation to disease stage and localization

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Changes in quality of life after hormonal treatment of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

The treatment of endometriosis: a review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Endometriosis: aetiology, pathogenesis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

1 reference

7 January 2021

Rofecoxib: clinical pharmacology and clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Danazol for pelvic pain associated with endometriosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Danazol: endocrine consequences in healthy women.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Danazol inhibits steroidogenesis by the human ovary in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Effects of danazol, gonadotropin-releasing hormone agonist, and a combination of danazol and gonadotropin-releasing hormone agonist on experimental endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Danazol: endocrine pharmacology and therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis after conservative surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Treatment of endometriosis with danazol: report of a 6-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Circulating lipid and lipoprotein concentrations during danazol and high-dose medroxyprogesterone acetate therapy of endometriosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Fatal acute hepatic failure induced by danazol in a patient with endometriosis and aplastic anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Very low dose danazol for relief of endometriosis-associated pelvic pain: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Low-dose danazol after combined surgical and medical therapy reduces the incidence of pelvic pain in women with moderate and severe endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Progestins for symptomatic endometriosis: a critical analysis of the evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Hypophysial Responses to Continuous and Intermittent Delivery of Hypothalamic Gonadotropin-Releasing Hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

A comparative study of the acceptability and effect of goserelin and nafarelin on endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Effects of triptorelin versus placebo on the symptoms of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Nafarelin in the treatment of pelvic pain caused by endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Buserelin versus danazol in the treatment of endometriosis-associated infertility

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Timing of initiation and dose schedule of leuprolide influence the time course of ovarian suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Buserelin acetate in the treatment of pelvic pain associated with minimal and mild endometriosis: a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Hormone treatment of endometriosis: the estrogen threshold hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Gonadotropin-releasing hormone agonist plus "add-back" hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Endometrial effects of long-term low-dose administration of RU486

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Endometrial patterns during therapy with danazol or gestrinone for endometriosis: structural and ultrastructural study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Updating the clinical experience in endometriosis – the Brazilian perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Updating the clinical experience in endometriosis – the European perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Gestrinone versus a gonadotropin-releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomized, double-blind study. Gestrinone Italian Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

A randomized comparative study of the metabolic effects of two regimens of gestrinone in the treatment of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Recurrent endometriosis: a review of biological and clinical aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Historical prospective cohort study of the recurrence of pain after discontinuation of treatment with danazol or a gonadotropin-releasing hormone agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

The morphologic effect of short-term medical therapy of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Postsurgical medical treatment of advanced endometriosis: Results of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Effects of 3 month therapy with danazol after laparoscopic surgery for stage III/IV endometriosis: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Molecular basis for treating endometriosis with aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Estrogen biosynthesis in endometriosis: molecular basis and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Treatment of severe postmenopausal endometriosis with an aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Immunobiology of endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Treating endometriosis as an autoimmune disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Immunomodulation of rat endometriotic implant growth and protein production

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2802%2900057-8

7 January 2021

Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. The Zoladex Endometriosis Study Group

8

1 reference

https://api.crossref.org/works/10.1016/S0889-8545(02)00057-8

Endometrial patterns during danazol and buserelin therapy for endometriosis: comparative structural and ultrastructural study

24 December 2023

31

1 reference

https://api.crossref.org/works/10.1016/S0889-8545(02)00057-8

Variable effects of danazol on endometriosis at 4 low-dose levels

24 December 2023

42

1 reference

https://api.crossref.org/works/10.1016/S0889-8545(02)00057-8

Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis

24 December 2023

47

1 reference

https://api.crossref.org/works/10.1016/S0889-8545(02)00057-8

Efficacy and safety of intranasal buserelin acetate in the treatment of endometriosis: a review of six clinical trials and comparison with danazol

24 December 2023

60

1 reference

https://api.crossref.org/works/10.1016/S0889-8545(02)00057-8

Gonadotropin-releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial

24 December 2023

74

1 reference

https://api.crossref.org/works/10.1016/S0889-8545(02)00057-8

Should add-back therapy for endometriosis be deferred for optimal results?

24 December 2023

75

1 reference

https://api.crossref.org/works/10.1016/S0889-8545(02)00057-8

Long-term follow-up of endometriosis after two different therapies (Gestrinone and Buserelin)

24 December 2023

85

1 reference

https://api.crossref.org/works/10.1016/S0889-8545(02)00057-8

24 December 2023

Identifiers

1 reference

6 August 2017

1 reference